Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.

Cancer medicine - 1 Dec 2023

Jing Xiaoqian, Luo Zhiping, Wu Jiayan, Ye Feng, Li Jianfang, Song Zijia, Zhang Yaqi, Shi Minmin, Sun Huaibo, Fang Yi, Jiang Yimei, Ji Xiaopin

Abstract excerpt

BACKGROUND: Anti-PD1/PD-L1 antibody plus human epidermal growth factor receptor 2 (HER2) antibody and chemotherapy have become the new first-line therapy for HER2 overexpression-positive advanced gastric cancers (GC), suggesting that HER2 and PD-L1 play a vital role in guiding systemic treatment for patients with GC. This study aimed to depict the genomic and immune landscapes of Chinese patients with GC and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastric Cancer Management and Outcomes

Share to Genomics

Share to HER2/EGFR in Cancer Research

Share to Mutation

Share to Prognosis

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38050871
DOI: 10.1002/cam4.6765
PMCID: PMC10757096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.PMID 38050871Read ↗

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.Semantic proximity Read ↗

Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer.Semantic proximity Read ↗

HER2 Amplification and PD-L1 Expression in Advanced Gastric Cancer: Correlations, Clinical Implications, and Molecular CharacteristicsSemantic proximity Read ↗

Bridging genomics and phenomics of gastric carcinomaSemantic proximity Read ↗

Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, tumor mutation burden and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Clinicopathological Features of Epstein-Barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in Chinese Patients with Gastric CancerSemantic proximity Read ↗

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity Read ↗

Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.Semantic proximity Read ↗

Immunohistochemical‐Based Molecular Typing of ACRG Combined With Immune‐Associated PD ‐ L1 Expression Can Predict the Prognosis of Gastric CancerSemantic proximity Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune typeSemantic proximity Read ↗

Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.